longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Aytu BioPharma

AYTU

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI
  • Microsoft To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

    benzinga_article·2 days ago, 12:22 PM
    - Wall Street financial institutions have updated their price targets and ratings for several major publicly traded corporations. - Key adjustments include Piper Sandler raising Microsoft Corp target to $610, while TD Cowen downgraded Accelerant Holdings to Hold. - Additional rating changes involve firms like Morgan Stanley, Citigroup, and B of A Securities modifying forecasts for companies such as Jack Henry, Moderna, and Ferrari.
    ARX0.00%AYTU-0.96%
  • Ascendiant Capital maintains Buy rating on Aytu BioPharma, $15 price target

    TradingView·2 days ago, 09:56 AM
    AYTU-0.96%
  • Weekly Recap | Aytu BioPharma +7.55%, earnings beat estimates

    Weekly Review·Sep 26 at 06:06 AM
    AYTU-0.96%
  • Aytu BioPharma (AYTU) Fiscal Q4 2026 Earnings Call: EXXUA Growth and FY2027 Outlook

    TradingKey·Sep 22 at 11:43 PM
    AYTU-0.96%
  • Aytu Fiscal Q4 2026 Earnings: EXXUA Drives Revenue Growth

    TradingKey·Sep 22 at 09:11 PM
    AYTU-0.96%
  • AYTU: EXXUA launch drives growth in CNS therapeutics, with FY26 revenue at $66.4M

    Quartr·Sep 22 at 09:09 PM
    AYTU-0.96%
  • Aytu BioPharma GAAP EPS of $0.00 beats by $0.33, revenue of $16.1M beats by $3.82M

    businessinsider·Sep 22 at 08:30 PM
    AYTU-0.96%
  • AYTU BIOPHARMA, INC FY 2026: Revenue $57.57M, EPS ($1.16) — 10-K Summary

    TradingView·Sep 22 at 08:25 PM
    AYTU-0.96%
  • AYTU: EXXUA launch drove $6.6M in revenue, but overall sales fell 13% and net loss reached $14.3M

    Quartr·Sep 22 at 08:20 PM
    AYTU-0.96%
  • Aytu BioPharma Q4 FY26 net loss narrows to USD 15,000; revenue rises 6.4% to USD 16.1 million vs Q4 FY25

    PUBT·Sep 22 at 08:06 PM
    AYTU-0.96%
  • Options Volatility and Implied Earnings Moves Today, September 22, 2026

    Tip Ranks·Sep 22 at 11:05 AM
    KBH-1.70%THO+0.72%
  • The Global Fringe: Cross-Border Capital Shifts from Asian AI Giants to Niche US Players

    Global Report·Sep 22 at 10:14 AM
    SKHL+1.77%TOELY0.00%